卵巢癌
医学
肿瘤科
癌症治疗
疾病
重症监护医学
先天免疫系统
癌症
范围(计算机科学)
纳米载体
生物信息学
免疫系统
内科学
糖尿病学
阶段(地层学)
临床试验
梅德林
免疫编辑
靶向治疗
作者
Arti Vashist,Arti Vashist,Pandiaraj Manickam,Gopi Karuppaiah,Gabriela Perez Alvarez,Vianessa Andion Camargo,Sukanya Bhunia,Nagesh Kolishetti,Andrea Raymond,Adriana Yndart,Atul Vashist,Atul Vashist,Venkata Atluri,Carolyn D. Runowicz,Madhavan Nair
标识
DOI:10.1021/acsabm.5c00777
摘要
Ovarian cancer is a global silent killer in women and is the second most common cause of gynecologic cancer-related deaths. Despite significant research and advances in treatment, ovarian cancer treatment remains a challenge, as it is diagnosed in an advanced stage and has a very high rate of recurrence following initial therapy. There is a compelling need to develop effective therapeutics for the treatment of ovarian cancer. This review highlights the recent advancements in nanoparticle-based drug-delivery systems and their expanding scope of treatments and diagnostics in ovarian cancer. In this article, we provide an overview of the innate immune response elicited by external delivery carriers. The review details the ongoing progress in nanotechnology for ovarian cancer treatment, including advances in nanoimmunotherapy and the potential of nanoparticle-based formulations for combating ovarian cancer. Recent diagnostic and prognostic tools used for ovarian cancer have been elaborated. The review also underscores the role of artificial intelligence in advancing current clinical diagnosis protocols. Challenges and future perspectives of nanocarriers for ovarian cancer treatment are also discussed in detail. This review uniquely integrates the role of innate immune responses with advances in nanotechnology for ovarian cancer, providing a comprehensive and interdisciplinary perspective that has not been previously addressed.
科研通智能强力驱动
Strongly Powered by AbleSci AI